Center for Business and Economic Research - Ball State University


CBER Data Center
Projects and PublicationsEconomic IndicatorsWeekly CommentaryCommunity Asset InventoryManufacturing Scorecard

About

Commentaries are published weekly and distributed through the Indianapolis Business Journal and many other print and online publications. Disclaimer

RSS Feed

Disclaimer

The views expressed in these commentaries do not reflect those of Ball State University or the Center for Business and Economic Research.

Recent

Two Key Economic Lessons in One BillHoosiers face trade-offs and opportunity costs in the wake of SEA1.

Time to Fix Economic Development PolicyAllocating tax dollars to land development won’t cause economic growth.

The Unanticipated Effects of SB1Businesses, governments and households may all feel the effects.

The Stupidest of PoliciesThis whipsawing of tariff rates has unnerved financial markets, which on Wednesday, were toying with a liquidity crisis.

View archives

Top Tags

jobs and employment 261
economics 201
state and local government 188
education 186
economic development 171
indiana 171
budget and spending 145
taxes 144
law and public policy 142
workforce and human capital 139
Browse all tags
Reporter / Admin Login

November 30, 2009

CDC Breast Cancer Recommendation not Supported

The recent CDC recommendation to delay breast cancer screening until age 50 is exceptionally revealing. The first is the lamentably poor state of benefit cost analysis of the CDC. The other is the role this type of policymaking will play in rationing health care under the current bills before Congress.

The CDC recommendations have already suffered a devastating blow by a peer reviewed journal and I expect them to be reversed in the coming months. But I have some research experience in this matter. While working as an economist in West Virginia our university research center tracked health care outcomes in several rural clinics. In one clinic the mammography machine broke and was not replaced for several months. We examined this natural experiment and found that preliminary cancer detections spiked right after the machine was replaced – presumably because women were forced to delay testing. Our study was plagued with the common limitations of medical research – small sample sizes, difficult and costly patient follow-up. Still, our findings suggest that delaying mammograms across this population cost lives. The benefits of replacing the machine outweighed the cost of screening by tenfold. Furthermore, all the other studies we read said the same thing: breast cancer screening is a very low cost way to extend life and reduce morbidity. The number and quality of studies were so convincing we didn’t bother to publish our study. Yet the CDC cited no benefit-cost studies to accompany their recommendations. Their medical colleagues are already pouncing on them, so I’ll say no more. 

What concerns me though, isn’t bad research (better research is already fixing this problem)  What scares me is that under the House and Senate health care proposals, virtually every medical procedure will have this type of government dictate deciding very personal medical decisions.

The ‘Death Panels’ label employed by some opponents of parts of the current health care reform were a bad choice of words. It sounded too much like a jury deciding for or against care for an ailing individual. This vision was easily discredited. The truth is nothing as personal as a Death Panel. Under the current proposal the same type of groups that made the CDC’s recommendations will outline guidelines about which treatment will be offered under a government program (or subsidized insurance plan). Since the government plan will quickly swallow private insurance, these treatment guidelines will set restrictions on treatment. For example, pancreatic cancer patients are likely to receive only pain relief and hospice.

Happily, no right minded insurance company or doctor is going to follow the CDC guidelines. That’s simply good business. But it’s not just about business and policy. Like many American families today mine prays for friends and loved ones afflicted by the disease. When it comes to screening for a cancer that strikes so many women in the prime of their lives we want to risk erring on the side of caution. That is the decision most families make. We all deserve a government that lets us.

Link to this commentary: https://commentaries.cberdata.org/36/cdc-breast-cancer-recommendation-not-supported

Tags: health care


About the Author

Michael Hicks cberdirector@bsu.edu

Michael J. Hicks, PhD, is the director of the Center for Business and Economic Research and the George and Frances Ball distinguished professor of economics in the Miller College of Business at Ball State University. Note: The views expressed here are solely those of the author, and do not represent those of funders, associations, any entity of Ball State University, or its governing body.

© Center for Business and Economic Research, Ball State University

About Ball State CBER Data Center

Ball State CBER Data Center is one-stop shop for economic data including demographics, education, health, and social capital. Our easy-to-use, visual web tools offer data collection and analysis for grant writers, economic developers, policy makers, and the general public.

Ball State CBER Data Center (cberdata.org) is a product of the Center for Business and Economic Research at Ball State University. CBER's mission is to conduct relevant and timely public policy research on a wide range of economic issues affecting the state and nation. Learn more.

Terms of Service

Center for Business and Economic Research

Ball State University • Whitinger Business Building, room 149
2000 W. University Ave.
Muncie, IN 47306-0360
Phone:
765-285-5926
Email:
cber@bsu.edu
Website:
www.bsu.edu/cber
Facebook:
www.facebook.com/BallStateCBER
Twitter:
www.twitter.com/BallStateCBER
Close